NGS techniques, such as amplicon-based plasma NGS, were previously used to detect ROS1 rearrangements in the plasma of NSCLC patients with known targetable genotypes, either before initiating targeted therapy or during treatment. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.